Literature DB >> 17306507

Cognitive behavioural therapy for weight gain associated with antipsychotic drugs.

Yasser Khazaal1, Emmanuelle Fresard, Sophie Rabia, Anne Chatton, Stephane Rothen, Valentino Pomini, François Grasset, François Borgeat, Daniele Zullino.   

Abstract

BACKGROUND: Overweight and obesity are common concerns in individuals with severe mental disorders. In particular, antipsychotic drugs (AP) frequently induce weight gain. This phenomenon lacks current management and no previous controlled studies seem to use cognitive therapy to modify eating and weight-related cognitions. Moreover, none of these studies considered binge eating or eating and weight-related cognitions as possible outcomes. AIM: The main aim of this study is to assess the effectivity of cognitive and behavioural treatment (CBT) on eating and weight-related cognitions, binge eating symptomatology and weight loss in patients who reported weight gain during AP treatment.
METHOD: A randomized controlled study (12-week CBT vs. Brief Nutritional Education) was carried out on 61 patients treated with an antipsychotic drug who reported weight gain following treatment. Binge eating symptomatology, eating and weight-related cognitions, as well as weight and body mass index were assessed before treatment, at 12 weeks and at 24 weeks.
RESULTS: The CBT group showed some improvement with respect to binge eating symptomatology and weight-related cognitions, whereas the control group did not. Weight loss occurred more progressively and was greater in the CBT group at 24 weeks.
CONCLUSION: The proposed CBT treatment is particularly interesting for patients suffering from weight gain associated with antipsychotic treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306507     DOI: 10.1016/j.schres.2006.12.025

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  28 in total

1.  The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders.

Authors:  Vibeke Porsdal; Catherine Beal; Ole Kristian Kleivenes; Egil W Martinsen; Eva Lindström; Harriet Nilsson; Pär Svanborg
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

2.  Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial.

Authors:  Kornelia Gillhoff; Jens Gaab; Luljeta Emini; Caroline Maroni; Joachim Tholuck; Waldemar Greil
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 3.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

4.  [Not Available].

Authors:  Josephine Ho; Constadina Panagiotopoulos; Brian McCrindle; Silviu Grisaru; Tamara Pringsheim
Journal:  Paediatr Child Health       Date:  2012-10       Impact factor: 2.253

5.  Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth.

Authors:  Josephine Ho; Constadina Panagiotopoulos; Brian McCrindle; Silviu Grisaru; Tamara Pringsheim
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-08

Review 6.  Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject.

Authors:  Tongeji E Tungaraza
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-31

7.  Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth.

Authors:  Josephine Ho; Constadina Panagiotopoulos; Brian McCrindle; Silviu Grisaru; Tamara Pringsheim
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

8.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

Review 9.  Addressing cardiometabolic risk during treatment with antipsychotic medications.

Authors:  Jonathan M Amiel; Christina V Mangurian; Rohan Ganguli; John W Newcomer
Journal:  Curr Opin Psychiatry       Date:  2008-11       Impact factor: 4.741

10.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Authors:  Virginia L Stauffer; Ilya Lipkovich; Vicki Poole Hoffmann; Alexandra N Heinloth; H Scott McGregor; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-03-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.